Patent intelligence · US
US 2009239858
THERAPEUTIC AMIDES
THERAPEUTIC AMIDES
Patent details — US 2009239858
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 24, 2009
- Expiration
- Sep 19, 2029
- Applicant
- ALLERGAN INC [US]
- CPC classes
- A61K 31/ 38 A I, A61K 31/ 381 A I, A61K 31/ 5377 A I, A61P 17/ 14 A I
Quick answer
US 2009239858 (THERAPEUTIC AMIDES) is held by ALLERGAN INC [US]. Status: granted. Granted Sep 24, 2009. Expires Sep 19, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALLERGAN INC [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 38 A I, A61K 31/ 381 A I, A61K 31/ 5377 A I, A61P 17/ 14 A I, A61P/1714, A61P/500
More from ALLERGAN INC [US]
Related pharmaceutical patents in our USPTO index.
-
CN 112638413
Oral immunotherapy unit dose dispensing systems and methods
granted -
WO 2015187736
FORMULATIONS PLACEBO ET UTILISATIONS DE CELLES-CI
granted -
US 2014356438
PERIPHERALLY ADMINISTERED VISCOUS FORMULATIONS
granted -
US 2014271721
PEANUT FORMULATIONS AND USES THEREOF
granted -
US 2014271836
MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION
granted -
US 2013209398
CONDITIONED CELL CULTURE MEDIUM COMPOSITIONS AND METHODS OF USE
granted -
CA 2849366
COMPOSITIONS ET PROCEDES POUR TRAITER LA PRESBYTIE, L'HYPERMETROPIE LEGERE ET L'ASTIGMATISME IRREGULIER
granted -
US 2012003230
SUSTAINED RELEASE DRUG DELIVERY SYSTEMS COMPRISING A WATER SOLUBLE THERAPEUTIC AGENT AND A RELEASE MODIFIER
granted
Frequently asked questions
What is US patent 2009239858?
US 2009239858 (THERAPEUTIC AMIDES) is held by ALLERGAN INC [US]. Status: granted. Granted Sep 24, 2009. Expires Sep 19, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2009239858?
ALLERGAN INC [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 24 pharmaceutical patents for this assignee.
When does US 2009239858 expire?
Our index shows an expiration date of Sep 19, 2029 (3 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.